Vivo Bio tech Ltd. — Capital/Financing Update 2025

Feb 20, 2025

==> picture [287 x 68] intentionally omitted <==

February 20, 2025

To, The Manager Dept of Corporate Services BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400001

Dear Sir/Madam,

Subject : Allotment of Convertible Equity Warrants Reference : Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Scrip Code : 511509

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that consequent to the special resolution passed by the shareholders of the Company at an Extra-Ordinary General Meeting convened on Friday, February 07, 2025 for issuance of 1,00,00,000 convertible equity warrants and pursuant to the in-principle approval given by BSE Ltd vide their letter LOD/PREF/TT/FIP/1823/2024-25 dated February 17, 2025, the Stakeholders Relationship Committee at its meeting held today i.e. Thursday, February 20, 2025 has approved the allotment of 21,33,333 (TwentyOne Lakh Thirty-Three Thousand Three Hundred and Thirty-Three only) convertible equity warrants at an Issue Price of Rs.45/- (Face Value of Rs.10/- and Premium of Rs.35/-) on preferential basis in accordance with SEBI (ICDR) Regulations, 2018, to the following persons on receipt of the subscription amount equivalent to 25% of the Issue Price:

S.No Name of Allottees Category	No. of Warrants Allotted
1 Antique Infotech Private Limited Public	21,33,333
TOTAL	21,33,333

We would further like to state that fully paid-up equity shares of face value of Rs. 10/- each of the Company against each Warrant shall be allotted on receipt of balance 75% of the issue price for each Warrant.

Pursuant to above allotment of Warrants, presently there is no change in the paid-up share capital of the Company.

The details as required under the Regulation 30 of the SEBI Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, is enclosed as Annexure I.

==> picture [562 x 79] intentionally omitted <==

==> picture [287 x 68] intentionally omitted <==

This is for your information and records.

Thanking You, Yours faithfully For Vivo Bio Tech Limited Ayinampudi Digitally signed by Ayinampudi Vaishnavi Vaishnavi Kiran Date: 2025.02.20 Kiran 14:09:54 +05'30' A V Kiran Company Secretary

==> picture [562 x 79] intentionally omitted <==

==> picture [287 x 68] intentionally omitted <==

Annexure-I

Details as required under Regulation 30 of the Listing Regulations read with Master Circular issued by SEBI vide circular no. SEBI/HO/CFD/PoD2/CIR/P/2023/120 dated July 11, 2023 (“Master Circular”).

==> picture [436 x 562] intentionally omitted <==

----- Start of picture text -----

S.No. Particulars Disclosure
1. Type of securities Fully Convertible Equity Warrants (“Warrants”)
proposed to be
Issued
2. Type of issuance Preferential Issue
3. Outcome of the The following are details of outcome of subscription:
Subscription, type Preferential Issue Issued Subscribed and
of issue, type of of allotted in this
securities and tranche
total number of Warrants 1,00,00,000 21,33,333
securities 21,33,333 (Twenty-One Lakh Thirty-Three Thousand Three
Hundred and Thirty-Three only) convertible equity warrants
allotted at an Issue Price of Rs.45/- (Face Value of Rs.10/- and
Premium of Rs.35/-) on receipt of 25% subscription amount
aggregating to Rs. 2,40,00,000/- (Rupees Two Crore Forty Lakh
only).
4. Name and number
of the Investor(s) S.No. Names of the Category No. of Warrants
Allottees
1. Antique Public 21,33,333
Infotech Private
Limited
Total 21,33,333
5. Post allotment of
securities - Category Pre preferential Post preferential
outcome of the issue issue
subscription. No of % No of %
Shares Shares
Promoters 62,71,500 38.88 62,71,500 34.34
and
Promoter
Group (A)
Public (B) 98,57,020 61.12 1,19,90,353 65.66
Non- 0 0 0 0
Promoter-
Non Public
Shareholding
(C)
Total (A) + 1,61,28,520 100 1,82,61,853 100
(B)+(C)
----- End of picture text -----*

==> picture [562 x 79] intentionally omitted <==

==> picture [287 x 68] intentionally omitted <==

		* The above post-issue shareholding is prepared assuming conversion of Warrants (allotted) into equity shares, pursuant to thispreferential issue.
6.	Intimation on conversion of securities or on lapse of the tenure of the instrument	The tenure of the Warrants shall not exceed 18 (eighteen) months from the date of allotment. Each warrant would be convertible into 1 Equity Share and the rights attached to Warrants can be exercised in one or more tranches, within 18 (eighteen months) from the date of allotment of such warrants. In the event that a Warrant holder does not exercise the Warrants within a period of 18 (eighteen) months from the date of allotment of such warrants, the unexercised Warrants shall lapse and the amount paid by that Warrant holder on such Warrants shall stand forfeited bythe Company.
7.	Nature of Consideration	Cash
8.	Any cancellation or termination of proposal for issuance of securities including reasons thereof	Not applicable

Warrants have been allotted upon receipt of 25% of the total consideration (i.e receipt of Rs. 11.25/- per warrant - out of the total of Rs. 45/- per warrant) and are convertible into equal number of equity shares upon receipt of the balance amount i.e., Rs. 33.75/- per warrant, within the stipulated time.

==> picture [562 x 79] intentionally omitted <==